Mind Medicine (MindMed) Inc.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
60255C885
SEDOL
N/A
CIK
0001813814
www.mindmed.co
LEI:
©
FIGI: BBG00F13HYQ7
MNMD
Mind Medicine (MindMed) Inc.
GICS: - · Sektor: Healthcare · Sub-Sektor: Biotechnology
NAME
Mind Medicine (MindMed) Inc.
ISIN
CA60255C8850
TICKER
MNMD
MIC
XNAS
REUTERS
MNMD.OQ
BLOOMBERG
MNMD US
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
GIF DE 728x90
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mo., 09.09.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 70,000 common shar...
weiterlesen
Mind Medicine
Research & Analysen Termsheet Terminal
Permalink
Mi., 04.09.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences: H.C. Wainwright 26th Annual Global Investm...
weiterlesen
Mind Medicine
Research & Analysen Termsheet Terminal
Permalink
Di., 13.08.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended June 30, 2024, and provided a business update. “Building on the positive momentum from our Phase 2b ...
weiterlesen
Mind Medicine
Research & Analysen Termsheet Terminal
Permalink
Fr., 09.08.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 9,285,511 common shares, without par value, at a public offering price of $7.00 per common share,...
weiterlesen
Mind Medicine
Research & Analysen Termsheet Terminal
Permalink
Fr., 09.08.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common sh...
weiterlesen
Mind Medicine
Research & Analysen Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements